A 16-month-long experience of COVID-19 in allogeneic haematopoietic stem cell transplantation recipients: An SFGM-TC multicentre cohort study.
Aliénor XhaardConstance XhaardMarie-Therese RubioAna BerceanuCarmen Botella-GarciaTereza ComanEmmanuelle TavernierHélène Labussière-WalletPatrice ChevallierFaezeh LegrandAnne ThiebautAnne-Lise MenardCatherine PaillardSylvain ChantepieMarie RobinStephanie NguyenPublished in: British journal of haematology (2023)
This 16-month-long multicentre retrospective study of 225 allogeneic haematopoietic stem cell transplantation (alloHSCT) recipients with COVID-19 examines risk factors for severity and mortality, describing the successive waves of infections (from March to June 2020 and from August 2020 to June 2021). We confirm the negative role of low respiratory tract disease and immunosuppressive treatment. We highlight significantly lower percentages of severe forms and COVID-19-related mortality during the second wave. Monthly comparative evolution of cases in alloHSCT recipients and in the French population shows a higher number of cases in alloHSCT recipients during the first wave and a decrease from February 2021.
Keyphrases
- stem cell transplantation
- coronavirus disease
- sars cov
- high dose
- respiratory tract
- kidney transplantation
- clinical trial
- cardiovascular events
- study protocol
- risk factors
- respiratory syndrome coronavirus
- cross sectional
- coronary artery disease
- double blind
- randomized controlled trial
- type diabetes
- early onset
- bone marrow
- smoking cessation